Status:

RECRUITING

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Lead Sponsor:

Hoffmann-La Roche

Conditions:

Alzheimers Disease

Eligibility:

All Genders

50-90 years

Phase:

PHASE3

Brief Summary

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

Eligibility Criteria

Inclusion

  • \- Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.

Exclusion

  • Dependency in basic activities of daily living (bADLs) due to cognitive impairment
  • Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)
  • Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
  • History of severe, clinically significant central nervous system trauma
  • Any serious medical condition that precludes a participant's safe participation and completion of a clinical study

Key Trial Info

Start Date :

July 2 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 31 2035

Estimated Enrollment :

13000 Patients enrolled

Trial Details

Trial ID

NCT07177352

Start Date

July 2 2025

End Date

July 31 2035

Last Update

December 19 2025

Active Locations (179)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 45 (179 locations)

1

Banner Alzheimer?s Institute

Phoenix, Arizona, United States, 85006

2

Banner Sun Health Research Institute

Sun City, Arizona, United States, 85351

3

Sun Valley Research Center, Inc.

Imperial, California, United States, 92251

4

Inglewood Clinicals

Inglewood, California, United States, 90301